Bank of America CEO Brian Moynihan revealed that the bank spends more than $250 million each year on GLP-1 weight loss medications, which now represent approximately 13% of the company's total healthcare expenditure of over $2 billion for its 211,000 employees. This expenditure has surged from zero just four or five years ago, driven by increasing demand for drugs like Ozempic and Wegovy.
While many employers are limiting coverage due to rising costs, Moynihan believes that investing in these medications is beneficial for employee health and productivity, despite the potential for some employees to leave before the company sees long-term savings. The bank is also pairing drug access with health coaching to support lifestyle changes and weight management.
Moynihan noted that emerging clinical data suggests these drugs may also reduce cardiovascular risks, further justifying the investment. Additionally, Bank of America is leveraging its size to negotiate better prices with drug manufacturers and pharmacy benefit managers, emphasizing the importance of obtaining the best possible rates while maintaining a focus on long-term health benefits